Three Key Things Every CAR-T Investor Should Observe – The Motley Loser
Three Key Things Every CAR-T Investor Should Observe
A long-awaited breakthrough in cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy, could ultimately hit the market later this year.
First-to-market advantage will likely to go Novartis (NYSE:NVS) with its drug named CTL019. Recently, a panel of FDA advisors unanimously recommended approval for CTL019, which will likely receive a final stamp of approval from the agency by early October. Other notable CAR-T players will be following closely behind, such as Kite Pharma (NASDAQ:KITE) and Juno Therapeutics (NASDAQ:JUNO) as a multi-billion dollar oncology market is up for grabs.
Pic source: Getty Pics.
But the very strength of CAR-T therapy — using a patient’s own cells to fight cancer — could also be its Achilles’ heel.
Here are three things every CAR-T investor should keep an eye on:
1. Is CAR-T safe?
“One of the most arousing things I’ve seen in my lifetime” is how one FDA pro described CAR-T therapy. And it’s effortless to see why.
Remarkably, 83% of patients taking Novartis’ CTL019 for a infrequent form of childhood leukemia were put into accomplish remission where all measurable signs of cancer had disappeared. But, incredible as this is, CAR-T is not without its risks.
CAR-T comes with potentially dangerous short-term side effects. Cytokine release syndrome (CRS) is a severe immune reaction to CAR-T that can include high-grade fevers, seizures, irregular heartbeat, and confusion. Novartis hopes to combat CRS with an extensive training plan and treatment algorithm to help medical professionals administering CAR-T.
CAR-T can also have devastating, sometimes fatal, effects on the jumpy system. Cerebral edema, or severe brain full salute, led to numerous deaths in trials for Juno and Kite. As a result, Juno had to shelve its lead product, JCAR015, along with its first-to-market advantage in the CAR-T race.
Just how much of a risk this poses, no one indeed knows. But Novartis is proposing to go after patients for up to fifteen years post-infusion, and, as CAR-T goes mainstream, I suspect other CAR-T players will go after suit.
Two. Can CAR-T be reliably manufactured?
“Living drugs” like CAR-T therapy can present elaborate production challenges. With such a very personalized therapy, each batch of CAR-T treatment embarks and finishes with the patient. This means that CAR-T is only as good as the beginning composition of cells it’s made from.
T-cells are very first collected from the patient and then genetically transformed into a CAR-T cell in a special lab. These CAR-T cells are then frozen before being returned to the patient for reinfusion. The entire process can take several weeks from beginning to end.
Isolating and modifying the right cells while leaving out the impurities — specifically, other immune cells — is a critical step in this entire process. A separate retrospective explore documented two cases in which a cancerous B-cell was mistakenly modified, becoming resistant to the CAR-T therapy and ultimately resulting in relapses.
So reliably controlling for the safety, purity, and potency of each individual CAR-T batch will present a logistical challenge. Interestingly, this could be where embattled biotech Juno Therapeutics has an edge. Juno’s fresh lead CAR-T candidate, JCAR017, uses a defined population of T-cells from the patient with the hopes of leading to less variability in the purity of the end product.
First-to-market advantage is significant, but the company that can best control this patient-to-patient variability — while keeping manufacturing failures and costs to a minimum — will ultimately be the winner in this race.
Three. Can CAR-T be profitable?
Assuming the safety profile for CAR-T therapy remains favorable and the drug can be reliably manufactured, the real question is, can CAR-T be profitable?
Novartis is originally restricting use of its CAR-T to just 30-35 specially trained medical centers.This will require patients to either travel to these sites or stay in the area for adequate post-infusion monitoring.
Due to the safety concerns, Novartis has also proposed a Risk Evaluation Mitigation Strategy (REMS) which will limit therapy to patients meeting certain prescribing criteria and require close monitoring. Novartis also plans to assign a single dedicated team to each patient to ensure chain-of-command logistics are followed at every step. Rest assured, all of this means CAR-T production will be no cheap endeavor and CAR-T pricing — some analysts suggesting upwards of $600,000 — will likely reflect this.
Another key question will be insurance coverage, and at what stage, for CAR-T. In the Novartis JULIET trial, out of one hundred forty one patients, nine could not be successfully infused with CAR-T due to manufacturing failures. Who will pick up the tab for these manufacturing misses? Will coverage only kick in when a patient is eventually treated with CAR-T? Will coverage become dependent upon successful treatment outcomes? All eyes will be on Novartis’ CTL019 as it sets the stage for what could be a contentious pricing and reimbursement debate.
Shannon Jones wields shares of Juno Therapeutics and Kite Pharma. The Motley Loser recommends Juno Therapeutics. The Motley Idiot has a disclosure policy.
Trio Key Things Every CAR-T Investor Should Observe – The Motley Idiot
Three Key Things Every CAR-T Investor Should Witness
A long-awaited breakthrough in cancer treatment, chimeric antigen receptor T-cell (CAR-T) therapy, could eventually hit the market later this year.
First-to-market advantage will likely to go Novartis (NYSE:NVS) with its drug named CTL019. Recently, a panel of FDA advisors unanimously recommended approval for CTL019, which will likely receive a final stamp of approval from the agency by early October. Other notable CAR-T players will be following closely behind, such as Kite Pharma (NASDAQ:KITE) and Juno Therapeutics (NASDAQ:JUNO) as a multi-billion dollar oncology market is up for grabs.
Photo source: Getty Photos.
But the very strength of CAR-T therapy — using a patient’s own cells to fight cancer — could also be its Achilles’ heel.
Here are three things every CAR-T investor should keep an eye on:
1. Is CAR-T safe?
“One of the most arousing things I’ve seen in my lifetime” is how one FDA pro described CAR-T therapy. And it’s effortless to see why.
Remarkably, 83% of patients taking Novartis’ CTL019 for a infrequent form of childhood leukemia were put into finish remission where all measurable signs of cancer had disappeared. But, incredible as this is, CAR-T is not without its risks.
CAR-T comes with potentially dangerous short-term side effects. Cytokine release syndrome (CRS) is a severe immune reaction to CAR-T that can include high-grade fevers, seizures, irregular heartbeat, and confusion. Novartis hopes to combat CRS with an extensive training plan and treatment algorithm to help medical professionals administering CAR-T.
CAR-T can also have devastating, sometimes fatal, effects on the jumpy system. Cerebral edema, or severe brain erection, led to numerous deaths in trials for Juno and Kite. As a result, Juno had to shelve its lead product, JCAR015, along with its first-to-market advantage in the CAR-T race.
Just how much of a risk this poses, no one truly knows. But Novartis is proposing to go after patients for up to fifteen years post-infusion, and, as CAR-T goes mainstream, I suspect other CAR-T players will go after suit.
Two. Can CAR-T be reliably manufactured?
“Living drugs” like CAR-T therapy can present complicated production challenges. With such a very personalized therapy, each batch of CAR-T treatment commences and finishes with the patient. This means that CAR-T is only as good as the commencing composition of cells it’s made from.
T-cells are very first collected from the patient and then genetically transformed into a CAR-T cell in a special lab. These CAR-T cells are then frozen before being returned to the patient for reinfusion. The entire process can take several weeks from beginning to end.
Isolating and modifying the right cells while leaving out the impurities — specifically, other immune cells — is a critical step in this entire process. A separate retrospective investigate documented two cases in which a cancerous B-cell was mistakenly modified, becoming resistant to the CAR-T therapy and ultimately resulting in relapses.
So reliably controlling for the safety, purity, and potency of each individual CAR-T batch will present a logistical challenge. Interestingly, this could be where embattled biotech Juno Therapeutics has an edge. Juno’s fresh lead CAR-T candidate, JCAR017, uses a defined population of T-cells from the patient with the hopes of leading to less variability in the purity of the end product.
First-to-market advantage is significant, but the company that can best control this patient-to-patient variability — while keeping manufacturing failures and costs to a minimum — will ultimately be the winner in this race.
Trio. Can CAR-T be profitable?
Assuming the safety profile for CAR-T therapy remains favorable and the drug can be reliably manufactured, the real question is, can CAR-T be profitable?
Novartis is primarily restricting use of its CAR-T to just 30-35 specially trained medical centers.This will require patients to either travel to these sites or stay in the area for adequate post-infusion monitoring.
Due to the safety concerns, Novartis has also proposed a Risk Evaluation Mitigation Strategy (REMS) which will limit therapy to patients meeting certain prescribing criteria and require close monitoring. Novartis also plans to assign a single dedicated team to each patient to ensure chain-of-command logistics are followed at every step. Rest assured, all of this means CAR-T production will be no cheap endeavor and CAR-T pricing — some analysts suggesting upwards of $600,000 — will likely reflect this.
Another key question will be insurance coverage, and at what stage, for CAR-T. In the Novartis JULIET trial, out of one hundred forty one patients, nine could not be successfully infused with CAR-T due to manufacturing failures. Who will pick up the tab for these manufacturing misses? Will coverage only kick in when a patient is ultimately treated with CAR-T? Will coverage become dependent upon successful treatment outcomes? All eyes will be on Novartis’ CTL019 as it sets the stage for what could be a contentious pricing and reimbursement debate.
Shannon Jones possesses shares of Juno Therapeutics and Kite Pharma. The Motley Loser recommends Juno Therapeutics. The Motley Loser has a disclosure policy.